Crystal Forms of the Antibiotic 4-Aminosalicylic Acid: Solvates and Molecular Salts with Dioxane, Morpholine, and Piperazine

2009 ◽  
Vol 9 (12) ◽  
pp. 5108-5116 ◽  
Author(s):  
Vânia André ◽  
Dario Braga ◽  
Fabrizia Grepioni ◽  
M. Teresa Duarte
Keyword(s):  
Aminosalicylic Acid ◽  
Crystal Forms ◽  
Molecular Salts

From pipemidic acid molecular salts to metal complexes and BioMOFs using mechanochemistry

CrystEngComm ◽  
2021 ◽  
Author(s):  
Martin Zábranský ◽  
Paula C. Alves ◽  
Catarina Bravo ◽  
M. Teresa Duarte ◽  
Vânia André
Keyword(s):  
Metal Complexes ◽  
Pipemidic Acid ◽  
Crystal Forms ◽  
Molecular Salts ◽  
Old Drugs

Mechanochemistry has proven to be an excellent sustainable, efficient and fast tool for the discovery of new crystal forms of old drugs.

Expanding the Pool of Multicomponent Crystal Forms of the Antibiotic 4-Aminosalicylic Acid: The Influence of Crystallization Conditions

2017 ◽  
Vol 17 (12) ◽  
pp. 6417-6425 ◽  
Author(s):  
Vânia André ◽  
Oleksii Shemchuk ◽  
Fabrizia Grepioni ◽  
Dario Braga ◽  
M. Teresa Duarte
Keyword(s):  
Aminosalicylic Acid ◽  
Crystal Forms ◽  
Influence Of Crystallization ◽  
Crystallization Conditions

Multiple Crystal Forms of p-Aminosalicylic Acid: Salts, Salt Co-Crystal Hydrate, Co-Crystals, and Co-Crystal Polymorphs

2012 ◽  
Vol 13 (1) ◽  
pp. 360-366 ◽  
Author(s):  
Pramod Kumar Goswami ◽  
Ram Thaimattam ◽  
Arunachalam Ramanan
Keyword(s):  
Crystal Hydrate ◽  
Aminosalicylic Acid ◽  
Crystal Forms ◽  
Acid Salts

scholarly journals New crystal forms of the antibiotic 4-aminosalicylic acid

2009 ◽  
Vol 65 (a1) ◽  
pp. s300-s301 ◽  
Author(s):  
Vânia André ◽  
Dario Braga ◽  
Fabrizia Grepioni ◽  
Maria Teresa Duarte
Keyword(s):  
Aminosalicylic Acid ◽  
Crystal Forms

Crystal Engineering of Multicomponent Crystal Forms of p-Aminosalicylic Acid with Pyridine Based Coformers

2016 ◽  
Vol 16 (3) ◽  
pp. 1268-1281 ◽  
Author(s):  
Pramod Kumar Goswami ◽  
Ram Thaimattam ◽  
Arunachalam Ramanan
Keyword(s):  
Crystal Engineering ◽  
Aminosalicylic Acid ◽  
Crystal Forms

The low-resolution 3D-structure of porin, a channel-forming protein in E. coliouter membranes

1983 ◽  
Vol 41 ◽  
pp. 440-441
Author(s):  
A. Engel ◽  
D.L. Dorset ◽  
A. Massalski ◽  
J.P. Rosenbusch
Keyword(s):  
Crystal Packing ◽  
3D Structure ◽  
Gram Negative Bacteria ◽  
Protein Ratio ◽  
Crystal Forms ◽  
Large Molecules ◽  
Functional Studies ◽  
Voltage Dependent ◽  
Planar Membranes ◽  
Hexagonal Arrays

Porins represent a group of channel forming proteins that facilitate diffusion of small solutes across the outer membrane of Gram-negative bacteria, while excluding large molecules (>650 Da). Planar membranes reconstituted from purified matrix porin (OmpF protein) trimers and phospholipids have allowed quantitative functional studies of the voltage-dependent channels and revealed concerted activation of triplets. Under the same reconstitution conditions but using high protein concentrations porin aggregated to 2D lattices suitable for electron microscopy and image processing. Depending on the lipid-to- protein ratio three different crystal packing arrangements were observed: a large (a = 93 Å) and a small (a = 79 Å) hexagonal and a rectangular (a = 79 Å b = 139 Å) form with p3 symmetry for the hexagonal arrays. In all crystal forms distinct stain filled triplet indentations could be seen and were found to be morphologically identical within a resolution of (22 Å). It is tempting to correlate stain triplets with triple channels, but the proof of this hypothesis requires an analysis of the structure in 3 dimensions.

6-Mercaptopurine metaboline profile is optimized by azathioprine formulation and non-use of 5-aminosalicylic acid angents in patients with inflammatory bowel disease

2001 ◽  
Vol 120 (5) ◽  
pp. A625-A625 ◽  
Author(s):  
T STEVENS ◽  
J ACHKAR ◽  
A BRZEZINSKI ◽  
D SEIDNER ◽  
B LASHNER
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Aminosalicylic Acid ◽  
Inflammatory Bowel

Overview of Biological Therapy in Ulcerative Colitis: Current and Future Directions

2015 ◽  
Vol 24 (2) ◽  
pp. 203-213 ◽  
Author(s):  
Federica Furfaro ◽  
Cristina Bezzio ◽  
Sandro Ardizzone ◽  
Alessandro Massari ◽  
Roberto De Franchis ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Immunosuppressive Agents ◽  
Mucosal Healing ◽  
Aminosalicylic Acid ◽  
Proinflammatory Mediators ◽  
Experimental Drugs ◽  
New Treatments ◽  
Aggressive Clinical Course ◽  
Near Future

The treatment of ulcerative colitis (UC) has changed over the last decade. It is extremely important to optimize the therapies which are available nowadays and commonly used in daily clinical practice, as well as to stimulate the search for more powerful drugs for the induction and maintenance of sustained and durable remission, thus preventing further complications. Therefore, it is mandatory to identify the patients' prognostic variables associated with an aggressive clinical course and to test the most potent therapies accordingly.To date, the conventional therapeutic approach based on corticosteroids, salicylates (sulfasalazine, 5-aminosalicylic acid) or immunosuppressive agents is commonly used as a first step to induce and to maintain remission. However, in recent years, knowledge of new pathogenetic mechanisms of ulcerative colitis have allowed us to find new therapeutic targets leading to the development of new treatments that directly target proinflammatory mediators, such as TNF-alpha, cytokines, membrane migration agents, cellular therapies.The aim of this review is to provide the most significant data regarding the therapeutic role of drugs in UC and to give an overview of biological and experimental drugs that will become available in the near future. In particular, we will analyse the role of these drugs in the treatment of acute flare and maintenance of UC, as well as its importance in mucosal healing and in treating patients at a high risk of relapse.

Sign in / Sign up

Export Citation Format

Share Document